• AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter, prescription and hospital.

    AFT's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs.

  • Maxigesic global growth continues

    AFT Pharmaceuticals (‘AFT’) has reached agreement with privately-owned Swiss headquartered multinational pharmaceutical company, Acino Pharma AG (‘Acino’), to out-license the product line of its patented combination painkiller, Maxigesic, to a further 69 countries.

    To view the announcements please click here.

  • NZX

    Shares in AFT Pharmaceuticals Limited (“AFT”), began trading on the NZX Main Board and ASX on 22 December 2015, following the successful IPO that raised $35.6 million through the issue and sale of New and existing shares.

    To view the announcements please click here.

Share Price & Graph

0.00 0.0%
2:39AM 03/06/2020
0.51 12.5%
11:57AM 02/06/2020
View more



Key Dates

Financial Year End 31/03/2019
Financial Half Year End 30/09/2019
Annual Shareholders Meeting August 2019
FY2019 Full Year Results Announcement May 2019
Financial Year End 31/03/2020

Latest Investor

View our latest presentations

Sign up for a request to be invited onto
our email subscribers database.